To examine the effects of autologous sural nerve and adrenal medullary tissue intrastriatal cografts upon voluntary motor performance in parkinsonism, a non-human primate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model was employed to quantitatively assess skilled hand movements. Motor performance was studied in normal, MPTP-induced parkinsonian, and then cografted states. Reaction and movement times were prolonged and variability increased in experimental and control animals in the parkinsonian state. Animals undergoing autologous cografts demonstrated improved motor performance whereas the control animal continued in a chronic, stable parkinsonian state. Intrastriatal cografts of autologous adrenal medullary tissue and sural nerve resulted in good to excellent chromaffin cell survival. The mechanism of the restoration of function in the cografted monkeys remains to be determined.
BakayR.A.; AllenG.S.; ApuzzoM.; BorgesL.F.; BullardD.E.; OjemannG.A.; OldfieldE.H.; PennR.; PurvisJ.T.; TindallG.T.Preliminary report on adrenal medullary grafting from the American Association of Neurological Surgeons Graft Project.Prog. Brain. Res.82: 603–610; 1990.
2.
BankiewiczK.S.; OldfieldE.H.; ChiuehC.C.; DoppmanJ.L.; JacobowitzD.M.; KopinI.J.Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).Life Sci.39: 7–16; 1986.
3.
BankiewiczK.S.; PlunkettR.J.; KopinI.J.; JacobowitzD.M.; LondonW.T.; OldfieldE.H.Transient behavioral recovery in hemiparkinsonian primates after adrenal medullary allografts.Prog. Brain. Res.78: 543–549; 1988.
4.
BeckerJ.B.; CurranE.J.; FreedW.J.; PoltorakM.Mechanisms of action of adrenal medulla grafts: The possible role of peripheral and central dopamine systems.Prog. Brain. Res.82: 499–507; 1990.
5.
BingG.; NotterM.F.; HansenJ.T.; KelloggC.; KordowerJ.H.; GashD.M.Cografts of adrenal medulla with C6 glioma cells in rats with 6- hydroxydopamine-induced lesions.Neuroscience34: 687–697; 1990.
6.
BjorklundA.; DunnettS.B.; SteneviU.; LewisM.E.; IversenS.D.Reinnervation of the denervated striatum by substantia nigra transplants: Functional consequences as revealed by pharmacological and sensorimotor testing.Brain. Res.199: 307–333; 1980.
BrownV.J.; SchwarzU.; BowmanE.M.; FuhrP.; RobinsonD.L.; HallettM.Dopamine dependent reaction time deficits in patients with Parkinson's disease are task specific.Neuropsychologia31: 459–469; 1993.
9.
BurnsR.S.; ChiuehC.C.; MarkeyS.P.; EbertM.H.; JacobowitzD.M.; KopinI.J.The clinical syndrome of striatal dopamine deficiency: Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP).N. Engl. J. Med.312: 1418–1421; 1985.
10.
CurranE.J.; BeckerJ.B.Changes in blood-brain barrier permeability are associated with behavioral and neurochemical indices of recovery following intraventricular adrenal medulla grafts in an animal model of Parkinson's disease.Exp. Neurol.114: 184–192; 1991.
11.
DateI.; AsariS.; NishimotoA.; FeltenD.Cografts of adrenal medulla and peripheral nerve in a mouse model of Parkinson's disease.No. Shinkei. Geka.19: 811–815; 1991.
12.
DateI.; FeltenS.Y.; FeltenD.L.Cografts of adrenal medulla with peripheral nerve enhance the survivability of transplanted adrenal chromaffin cells and recovery of the host nigrostriatal dopaminergic system in MPTP-treated young adult mice.Brain. Res.537: 33–39; 1990.
13.
DavisG.C.; WilliamsA.C.; MarkeyS.P.; EbertM.H.; CaineE.D.; ReichertC.M.; KopinI.J.Chronic parkinsonism secondary to intravenous injection of meperidine analogs.Psychiatry Res.1: 249–254; 1979.
14.
DoeringL.C.Peripheral nerve segments promote consistent long-term survival of adrenal medulla transplants in the brain.Exp. Neurol.118: 253–260; 1992.
15.
DoupeA.J.; LandisSC; PattersonP.H.Environmental influences in the development of neural crest derivatives: Glucocorticoids, growth factors, and chromaffin cell plasticity.J. Neurosci.5(8): 2119–2142; 1985.
16.
DubachM.; GermanD.C.Extensive survival of chromaffin cells in adrenal medulla “ribbon” grafts in the monkey neostriatum.Exp. Neurol.110: 167–180; 1990.
17.
EllisJ.E.; ByrdL.D.; BakayR.A.A method for quantitating motor deficits in a nonhuman primate following MPTP-induced hemiparkinsonism and co-grafting.Exp. Neurol.115: 376–387; 1992.
18.
EvartsE.V.; TeravainenH.; CalneD.B.Reaction time in Parkinson's disease.Brain104: 167–186; 1981.
19.
FiandacaM.S.; KordowerJ.H.; HansenJ.T.; JiaoS.S.; GashD.M.Adrenal medullary autografts into the basal ganglia of Cebus monkeys: Injury-induced regeneration.Exp. Neurol.102: 76–91; 1988.
20.
GoetzC.G.; StebbinsG.T.; KlawansH.L.III; KollerW.C.; GrossmanR.G.; BakayR.A.; PennR.D.United Parkinson Foundation Neurotransplantation Registry: Multicenter US and Canadian data base, pre-surgical and 12 month follow-up.Prog. Brain Res.82: 611–617; 1990.
21.
HirschE.C.; DuyckaertsC.; Javoy AgidF.; HauwJ.J.; AgidY.Does adrenal graft enhance recovery of dopaminergic neurons in Parkinson's disease? Ann.Neurol.27: 676–682; 1990.
22.
HornykiewiczO.; KishS.J.Biochemical pathophysiology of Parkinson's disease.Adv. Neurol.45: 19–34; 1987.
23.
HurtigH.; JoyceJ.; SladekJ.R.Jr.; TrojanowskiJ.Q.Postmortem analysis of adrenal-medulla-to-caudate autograft in a patient with Parkinson's disease.Ann. Neurol.25: 607–614; 1989.
24.
JankovicJ.; GrossmanR.; GoodmanC.; PirozzoloF.; SchneiderL.; ZhuZ.; ScardinoP.; GarberA.J.; JhingranS.G.; MartinS.Clinical, biochemical, and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinson's disease.Neurology39: 1227–1234; 1989.
25.
KordowerJ.H.; CochranE.; PennR.D.; GoetzC.G.Putative chromaffin cell survival and enhanced host-derived TH- fiber innervation following a functional adrenal medulla autograft for Parkinson's disease.Ann. Neurol.29: 405–412; 1991.
26.
KordowerJ.H.; FiandacaM.S.; NotterM.F.; HansenJ.T.; GashD.M.NGF-like trophic support from peripheral nerve for grafted rhesus adrenal chromaffin cells.J. Neurosurg.73: 418–428; 1990.
27.
LangstonJ.W.; BallardP.A.; TetrudJ.W.; IrwinI.Chronic parkinsonism in humans due to a product of meperidine-analog synthesis.Science292: 390–394; 1983.
28.
LeviA.D.; GuenardV.; AebischerP.; BungeR.P.The functional characteristics of Schwann cells cultured from human peripheral nerve after transplantation into a gap within the rat sciatic nerve.J. Neurosci.14: 1309–1319; 1994.
29.
OlsonL.; SeigerA.; HofferB.; TaylorD.Isolated catecholaminergic projections from substantia nigra and locus coeruleus to caudate, hippocampus and cerebral cortex formed by intraocular sequential double brain grafts.Exp. Brain. Res35: 47–67; 1979.
30.
PetersonD.I.; PriceM.L.; SmallC.S.Autopsy findings in a patient who had an adrenal-to-brain transplant for Parkinson's disease.Neurology39: 235–238; 1989.
31.
PlunkettR.J.; BankiewiczK.S.; CumminsA.C.; MiletichR.S.; SchwartzJ.P.; OldfieldE.H.Long-term evaluation of hemiparkinsonian monkeys after adrenal autografting or cavitation alone.J. Neurosurg.73: 918–926; 1990.
32.
PrasherD.; FindleyL.Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: An electrophysiological investigation.J. Neurol. Neurosurg. Psychiatry54: 603–609; 1991.
33.
PullmanS.L.; WattsR.L.; JuncosJ.L.; ChaseT.N.; SanesJ.N.Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease.Neurology38: 249–254; 1988.
StrombergI.; Herrera MarschitzM.; UngerstedtU.; EbendalT.; OlsonL.Chronic implants of chromaffin tissue into the dopamine-denervated striatum. Effects of NGF on graft survival, fiber growth and rotational behavior.Exp. Brain. Res.60: 335–349; 1985.
41.
UnsickerK.; StogbauerF.Screening of adrenal med-ullary neuropeptides for putative neurotrophic effects.Int. J. Dev. Neurosci.10: 171–179; 1992.
WattsR.L.; BakayR.A.; HerringC.J.; SweeneyK.M.; ColbassaniH.J.; MandirA.; ByrdL.D.; IuvoneP.M.Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys.Prog. Brain. Res.82: 581–591; 1990.
44.
YongV.W.; GuttmanM.; KimS.U.; CalneD.B.; TurnbullI.; WatabeK.; TomlinsonR.W.Transplantation of human sympathetic neurons and adrenal chromaffin cells into parkinsonian monkeys: No reversal of clinical symptoms.J. Neurol. Sci.94: 51–67; 1989.
